Daito Pharmaceutical Co.,Ltd.

TSE:4577 Stock Report

Market Cap: JP¥30.7b

Daito PharmaceuticalLtd Balance Sheet Health

Financial Health criteria checks 5/6

Daito PharmaceuticalLtd has a total shareholder equity of ¥52.1B and total debt of ¥12.1B, which brings its debt-to-equity ratio to 23.3%. Its total assets and total liabilities are ¥81.9B and ¥29.8B respectively. Daito PharmaceuticalLtd's EBIT is ¥3.7B making its interest coverage ratio -406.9. It has cash and short-term investments of ¥4.7B.

Key information

23.3%

Debt to equity ratio

JP¥12.14b

Debt

Interest coverage ratio-406.9x
CashJP¥4.69b
EquityJP¥52.08b
Total liabilitiesJP¥29.85b
Total assetsJP¥81.93b

Recent financial health updates

No updates

Recent updates

Daito PharmaceuticalLtd's (TSE:4577) Weak Earnings May Only Reveal A Part Of The Whole Picture

Jul 19
Daito PharmaceuticalLtd's (TSE:4577) Weak Earnings May Only Reveal A Part Of The Whole Picture

Financial Position Analysis

Short Term Liabilities: 4577's short term assets (¥45.8B) exceed its short term liabilities (¥18.8B).

Long Term Liabilities: 4577's short term assets (¥45.8B) exceed its long term liabilities (¥11.1B).

Debt to Equity History and Analysis

Debt Level: 4577's net debt to equity ratio (14.3%) is considered satisfactory.

Reducing Debt: 4577's debt to equity ratio has increased from 14% to 23.3% over the past 5 years.

Debt Coverage: 4577's debt is well covered by operating cash flow (42.7%).

Interest Coverage: 4577 earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 01:03
End of Day Share Price 2024/12/24 00:00
Earnings2024/08/31
Annual Earnings2024/05/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Daito Pharmaceutical Co.,Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Masao YoshidaIchiyoshi Research Institute Inc.
Yukichi OkabeOkasan Securities Co. Ltd.
Takashi AkahaneTokai Tokyo Intelligence Laboratory Co., Ltd.